Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927144 · ClinicalTrials.gov registry record · Phase 4
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
A Phase 4 study of Episodic Migraine, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 621
- Enrollment target
- 20
- Study locations
NCT03927144 is a Phase 4 study of Episodic Migraine that has completed, run by Amgen. The registered enrollment target is 621 participants, above the 449-participant average among 13 other Episodic Migraine trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT03927144, a Phase 4 study of Episodic Migraine, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 621 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
Conditions Studied
Interventions
- DRUG AMG334
- DRUG Oral Prophylactic
Study Locations (20)
Connecticut
- Yale Center for Clinical Research - New Haven
- New England Institute for Neurology and Headache - Stamford
Florida
- University of Miami Headache Division - Miami
- Premier Research Institute - West Palm Beach
Illinois
- Diamond Headache Clinic - Chicago
- Robbins Headache Clinic - Riverwoods
Massachusetts
- Medvadis - Watertown
- New England Regional Headache Center, Inc - Worcester
Missouri
- Study Metrix Research - City of Saint Peters
- Mercy Health Research - St Louis
Texas
- Texas Neurology - Dallas
- Texas Institute for Neurological Disorders - Sherman
California
- Stanford Headache Center - Stanford
District of Columbia
- George Washington Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 621 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03927144
The ClinicalTrials.gov registry entry for NCT03927144 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 621 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 449-participant average among 13 other Episodic Migraine trials with a reported enrollment target (38% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which AMG334 is the first listed.
NCT03927144 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Connecticut, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03927144 about?
NCT03927144 is a clinical study titled "Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients". The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
What is the current status of trial NCT03927144?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 621 participants. The study started on 2019-05-15. Estimated completion is 2022-09-30.
What conditions does trial NCT03927144 study?
This clinical trial studies the following conditions: Episodic Migraine.
What interventions are being tested in trial NCT03927144?
The interventions under investigation include: AMG334 (DRUG), Oral Prophylactic (DRUG).
Who is sponsoring clinical trial NCT03927144?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03927144 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Episodic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
COMPLETED · Phase 4
-
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
COMPLETED · Phase 4
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
RECRUITING · Phase 3
-
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
RECRUITING · Phase 3
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RECRUITING
-
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.